Publications by authors named "Emmanuel Zuber"

Claim this Profile
E
End points in clinical trials in diffuse large B-cell lymphoma: time for more dialogue?
Evgeny Degtyarev, Natacha Bolaños, Joshua D Brody, Aby Buchbinder, Marc Buyse, Emmanuel Zuber

Future Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitoring overall survival in pivotal trials in indolent cancers.
Thomas R Fleming, Lisa V Hampson, Bharani Bharani-Dharan, Frank Bretz, Arunava Chakravartty, Emmanuel Zuber

Stat Biopharm Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decentralized Clinical Trials: Scientific Considerations Through the Lens of the Estimand Framework.
Rima Izem, Emmanuel Zuber, Nadia Daizadeh, Frank Bretz, Oleksandr Sverdlov

Ther Innov Regul Sci· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methodology for Good Machine Learning with Multi-Omics Data.
Thibaud Coroller, Berkman Sahiner, Anup Amatya, Alexej Gossmann, Konstantinos Karagiannis, Emmanuel Zuber

Clin Pharmacol Ther· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Predictive Individual Effect for Survival Data.
Beat Neuenschwander, Satrajit Roychoudhury, Simon Wandel, Kannan Natarajan, Emmanuel Zuber

Ther Innov Regul Sci· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges in Assessing the Impact of the COVID-19 Pandemic on the Integrity and Interpretability of Clinical Trials.
Mouna Akacha, Janice Branson, Frank Bretz, Bharani Dharan, Paul Gallo, Emmanuel Zuber

Stat Biopharm Res· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimands and the Patient Journey: Addressing the Right Question in Oncology Clinical Trials.
Evgeny Degtyarev, Yiyun Zhang, Kapildeb Sen, David Lebwohl, Mouna Akacha, Emmanuel Zuber

JCO Precis Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A proof of concept phase II non-inferiority criterion.
Beat Neuenschwander, Nicolas Rouyrre, Norbert Hollaender, Emmanuel Zuber, Michael Branson

Stat Med· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology.
Werner Brannath, Emmanuel Zuber, Michael Branson, Frank Bretz, Paul Gallo

Stat Med· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial.
Yung-Jue Bang, Won Ki Kang, Yoon-Koo Kang, Hugh Chul Kim, Christian Jacques, Emmanuel Zuber

Jpn J Clin Oncol· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis